Antiretroviral Nonadherence, Unsuppressed Viral Load Prevalent Across Adolescence
The prevalence of nonadherence and unsuppressed viral load increased through adolescence and into young adulthood.
Antiretrovirals
Dolutegravir and Two Tenofovir Prodrugs Noninferior to Standard HIV Regimens
Treatment with dolutegravir and either of 2 tenofovir prodrugs, tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, is noninferior to standard HIV antiretroviral regimes.
Long-Acting Two-Drug Injectable HIV Treatment Effective in Phase 3 Trial
Janssen announced positive top-line results from the phase 3 ATLAS-2M study evaluating the two-drug long-acting injectable regimen of rilpivirine (Janssen) and cabotegravir (ViiV Healthcare) administered every 2 months in patients with HIV-1 infection.
Majority of African Women Express Interest in Using HIV Antiretroviral Vaginal Ring
A majority of women were interested in and adhered to the use of a dapivirine vaginal ring to reduce their risk of contracting HIV.
Increases in HIV PrEP Awareness and Use Needed in High-Risk Populations
Although HIV PrEP awareness and use had increased from 2014 to 2017, increases in both areas are needed to reduce new HIV infections by 2030.
Labeling Updated for Bictegravir, Emtricitabine, Tenofovir Combination to Include Info on Neural Tube Defect Risk
The FDA has approved updated labeling for Biktarvy to include information regarding the risk of neural tube defects.
Compliance With ART Indirectly Related With Age in Adolescents Born With HIV
Prevalence of nonadherence increased from preadolescence to late adolescence/young adulthood
Advancing PrEP in the Southern United States
To improve steps along the PrEP care continuum for HIV prevention, sustainable program strategies are vital in the black and Latino MSM populations in the southern United States.
Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV
Although adding ibalizumab to an optimized background regimen of ART is not cost-effective, ibalizumab substantially increased survival for individuals with multidrug-resistant HIV.
Monthly Long-Acting Cabotegravir and Rilpivirine Noninferior to Oral ART
Monthly injections of long-acting formulations of cabotegravir and rilpivirine were noninferior to daily oral combination antiretroviral therapy for maintaining HIV-1 suppression and also offered improved treatment satisfaction.
Next post in HIV/AIDS
